BFA sends proteins back by Powell, Kendall
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From the Archive
O
bserving a step backward brought Jon 
Yewdell a big step forward in understand-
ing protein traffi   cking pathways in the 
cell. As a newly minted assistant professor at the 
Wistar Institute, Yewdell was examining where in 
the cell the infl  uenza A virus (IAV) hemagglutin 
(HA) trimerized. Using monoclonal antibodies 
(mAbs) specifi  c for monomers or trimers, he had 
found by 1985 that monomers localized to the en-
doplasmic reticulum (ER), whereas trimers were fi  rst detected 
in the Golgi complex without a trace of ER staining (Yewdell 
et al., 1988). And there the trimers might have stayed except 
for a chance conversation.
Hearing Yewdell’s seminar at Case Western Reserve 
University, Alan Tartakoff urged him to read Akira Takatsuki’s 
paper showing that the drug Brefeldin A (BFA) blocked 
transport from the ER (Misumi et al., 1986). Yewdell wrote 
to Takatsuki, who generously sent a glassine envelope with a 
few milligrams of powder.
Recruited to the National Institutes of Health in 1987, 
Yewdell forgot about BFA until the envelope tumbled out 
of a lab notebook while he was unpacking. He treated IAV-
infected cells with BFA, and observed for the first time 
ER staining with trimer-specific 
mAbs.
“After stumbling around in the 
dark for a suitable period,” says 
Yewdell, he eventually performed 
an intricate pulse-chase experiment 
in which he fi  rst blocked HA egress 
from the ER with BFA and then removed the BFA in the 
presence of cycloheximide to prevent new HA synthesis. Now, 
the trimers completely cleared the ER and moved to the Golgi 
on their way to the cell surface. When Yewdell added back BFA 
during the chase, HA trimers magically reappeared in the ER.
“I pretty much knew that I had discovered retrograde 
transport,” he says. Retrograde traffi  cking from the Golgi 
to ER had been suggested both for retrieval of ER resident 
proteins (Pelham, 1988) and recycling of lipids (Wieland et 
al., 1987). But no techniques could isolate this pathway from 
anterograde traffi  c.
Yewdell needed a method to prove that BFA was not 
holding up forward traffi   c but instead triggering reverse 
traffi   c. To get the experiment going he therefore needed 
to conditionally trap a marker protein in the ER without 
using BFA. So he recruited his friend Robert Doms (then 
a post-doctoral student in a neighboring lab). Doms had 
been studying a vesicular stomatitis virus temperature-
sensitive mutant that, at 40°C, produces a misfolded version 
of its membrane glycoprotein that is trapped in the ER. 
Shifting infected cells to 32°C released the protein. Using this 
system, they showed that BFA induced the retrograde transport 
of Golgi enzymes that could now modify oligosaccharides 
of the ER-retained glycoprotein (Doms et al., 1989). They 
concluded that BFA caused both resident Golgi proteins 
and those in transport to be shifted to the ER. Whether the 
mechanism was by an exaggerated recycling pathway or an 
artifi  cial fusion of the two organelles, the authors left open to 
further experimentation.
Simultaneously, Jennifer Lippincott-Schwartz, working 
with Richard Klausner, came to similar conclusions about 
BFA while tracking T cell receptors (Lippincott-Schwartz 
et al., 1989). “It was totally exciting when we saw the 
redistribution of Golgi back into ER,” she says. “It was 
the fi  rst example of organelle disassembly.” She says the 
two papers ignited the fi   elds of retrograde transport and 
Golgi biogenesis. Lippincott-Schwartz and colleagues later 
demonstrated that both normal retrograde traffi  cking and the 
Golgi–ER fusion seen with BFA occur via tubules (Sciaky 
et al., 1997).
Lippincott-Schwartz says the search for BFA’s target also 
“really boosted our understanding of the coatomer and Arf1 
proteins,” involved in retrograde transport. Arf1 is a key regulator 
of Golgi architecture, and it turns out that BFA stabilizes an 
Arf1 exchange factor, GBF1, on Golgi membranes (Niu et al., 
2005). This inactivates Arf1, leading to exaggerated retrograde 
traffi  cking and blocked anterograde traffi  c. The reversible drug 
is still widely used, especially to probe how the Golgi might 
reform after cell division.
“I would have never learned about BFA, except for the 
trimerization project,” recalls Yewdell. “Never pass up the 
opportunity to give a seminar—you never know who you 
will meet.” KP
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Adding BFA sends a protein from the Golgi (left) to ER (right).
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Jon Yewdell 
uses Brefeldin A 
to detect 
retrograde 
trafficking.